A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials

The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive fu...

Descripción completa

Detalles Bibliográficos
Autores: Sola Llopis, Susana de, Torre Fornell, Rafael de la, Sánchez Benavides, Gonzalo, Benejam, Bessy, Cuenca Royo, Aida Ma, 1981-, Del Hoyo Soriano, Laura, Rodríguez, Joan, Catuara Solarz, Silvina, 1986-, Sánchez Gutiérrez, Judit, Dueñas-Espín, Iván, 1979-, Hernández, Gimena, Peña-Casanova, J. (Jordi), Langohr, Klaus, Videla, Sebastià, Blehaut, Henry, Farré Albaladejo, Magí, Dierssen, Mara, TESDAD Study Group
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Universitat Pompeu Fabra
Repositorio:Repositorio Digital de la UPF
OAI Identifier:oai:repositori.upf.edu:10230/25039
Acceso en línea:http://hdl.handle.net/10230/25039
http://dx.doi.org/10.3389/fpsyg.2015.00708
Access Level:acceso abierto
Palabra clave:Cognició -- Investigació
Down, Síndrome de -- Aspectes genètics
TESDAD neuro cognitive battery
Intellectual disabilities
Cognition
Clinical trials as topic
Down syndrome
id ES_2129e52fca608fdcd5b492a86ff9e93d
oai_identifier_str oai:repositori.upf.edu:10230/25039
network_acronym_str ES
network_name_str España
repository_id_str
spelling A new cognitive evaluation battery for Down syndrome and its relevance for clinical trialsSola Llopis, Susana deTorre Fornell, Rafael de laSánchez Benavides, GonzaloBenejam, BessyCuenca Royo, Aida Ma, 1981-Del Hoyo Soriano, LauraRodríguez, JoanCatuara Solarz, Silvina, 1986-Sánchez Gutiérrez, JuditDueñas-Espín, Iván, 1979-Hernández, GimenaPeña-Casanova, J. (Jordi)Langohr, KlausVidela, SebastiàBlehaut, HenryFarré Albaladejo, MagíDierssen, MaraTESDAD Study GroupCognició -- InvestigacióDown, Síndrome de -- Aspectes genèticsTESDAD neuro cognitive batteryIntellectual disabilitiesCognitionClinical trials as topicDown syndromeThe recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.Frontiers201520152015info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfapplication/pdfhttp://hdl.handle.net/10230/25039http://dx.doi.org/10.3389/fpsyg.2015.00708reponame:Repositorio Digital de la UPFinstname:Universitat Pompeu FabraInglésFrontiers in psychology. 2015;6:708© 2015 de Sola, de la Torre, Sánchez-Benavides, Benejam, Cuenca- Royo, del Hoyo, Rodríguez, Catuara-Solarz, Sanchez-Gutierrez, Dueñas-Espin, Hernandez, Peña-Casanova, Langohr, Videla, Blehaut, Farre, Dierssen and The TESDAD Study Group.This is an open-access article distributed under the terms of the Creative Commons Attribution License (CCBY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licens or are credited and that the original publication in this journal is cited,in accordance with accepted academic practice. Nou se,distribution or reproduction is permitted which does not comply with these terms.http://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:repositori.upf.edu:10230/250392026-06-12T07:21:37Z
dc.title.none.fl_str_mv A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
spellingShingle A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
Sola Llopis, Susana de
Cognició -- Investigació
Down, Síndrome de -- Aspectes genètics
TESDAD neuro cognitive battery
Intellectual disabilities
Cognition
Clinical trials as topic
Down syndrome
title_short A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_full A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_fullStr A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_full_unstemmed A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
title_sort A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
dc.creator.none.fl_str_mv Sola Llopis, Susana de
Torre Fornell, Rafael de la
Sánchez Benavides, Gonzalo
Benejam, Bessy
Cuenca Royo, Aida Ma, 1981-
Del Hoyo Soriano, Laura
Rodríguez, Joan
Catuara Solarz, Silvina, 1986-
Sánchez Gutiérrez, Judit
Dueñas-Espín, Iván, 1979-
Hernández, Gimena
Peña-Casanova, J. (Jordi)
Langohr, Klaus
Videla, Sebastià
Blehaut, Henry
Farré Albaladejo, Magí
Dierssen, Mara
TESDAD Study Group
author Sola Llopis, Susana de
author_facet Sola Llopis, Susana de
Torre Fornell, Rafael de la
Sánchez Benavides, Gonzalo
Benejam, Bessy
Cuenca Royo, Aida Ma, 1981-
Del Hoyo Soriano, Laura
Rodríguez, Joan
Catuara Solarz, Silvina, 1986-
Sánchez Gutiérrez, Judit
Dueñas-Espín, Iván, 1979-
Hernández, Gimena
Peña-Casanova, J. (Jordi)
Langohr, Klaus
Videla, Sebastià
Blehaut, Henry
Farré Albaladejo, Magí
Dierssen, Mara
TESDAD Study Group
author_role author
author2 Torre Fornell, Rafael de la
Sánchez Benavides, Gonzalo
Benejam, Bessy
Cuenca Royo, Aida Ma, 1981-
Del Hoyo Soriano, Laura
Rodríguez, Joan
Catuara Solarz, Silvina, 1986-
Sánchez Gutiérrez, Judit
Dueñas-Espín, Iván, 1979-
Hernández, Gimena
Peña-Casanova, J. (Jordi)
Langohr, Klaus
Videla, Sebastià
Blehaut, Henry
Farré Albaladejo, Magí
Dierssen, Mara
TESDAD Study Group
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cognició -- Investigació
Down, Síndrome de -- Aspectes genètics
TESDAD neuro cognitive battery
Intellectual disabilities
Cognition
Clinical trials as topic
Down syndrome
topic Cognició -- Investigació
Down, Síndrome de -- Aspectes genètics
TESDAD neuro cognitive battery
Intellectual disabilities
Cognition
Clinical trials as topic
Down syndrome
description The recent prospect of pharmaceutical interventions for cognitive impairment of Down syndrome (DS) has boosted a number of clinical trials in this population. However, running the trials has raised some methodological challenges and questioned the prevailing methodology used to evaluate cognitive functioning of DS individuals. This is usually achieved by comparing DS individuals to matched healthy controls of the same mental age. We propose a new tool, the TESDAD Battery that uses comparison with age-matched typically developed adults. This is an advantageous method for probing the clinical efficacy of DS therapies, allowing the interpretation and prediction of functional outcomes in clinical trials. In our DS population the TESDAD battery permitted a quantitative assessment of cognitive defects, which indicated language dysfunction and deficits in executive function, as the most important contributors to other cognitive and adaptive behavior outcomes as predictors of functional change in DS. Concretely, auditory comprehension and functional academics showed the highest potential as end-point measures of therapeutic intervention for clinical trials: the former as a cognitive key target for therapeutic intervention, and the latter as a primary functional outcome measure of clinical efficacy. Our results also emphasize the need to explore the modulating effects of IQ, gender and age on cognitive enhancing treatments. Noticeably, women performed significantly better than men of the same age and IQ in most cognitive tests, with the most consistent differences occurring in memory and executive functioning and negative trends rarely emerged on quality of life linked to the effect of age after adjusting for IQ and gender. In sum, the TESDAD battery is a useful neurocognitive tool for probing the clinical efficacy of experimental therapies in interventional studies in the DS population suggesting that age-matched controls are advantageous for determining normalization of DS.
publishDate 2015
dc.date.none.fl_str_mv 2015
2015
2015
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/10230/25039
http://dx.doi.org/10.3389/fpsyg.2015.00708
url http://hdl.handle.net/10230/25039
http://dx.doi.org/10.3389/fpsyg.2015.00708
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Frontiers in psychology. 2015;6:708
dc.rights.none.fl_str_mv http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
application/pdf
dc.publisher.none.fl_str_mv Frontiers
publisher.none.fl_str_mv Frontiers
dc.source.none.fl_str_mv reponame:Repositorio Digital de la UPF
instname:Universitat Pompeu Fabra
instname_str Universitat Pompeu Fabra
reponame_str Repositorio Digital de la UPF
collection Repositorio Digital de la UPF
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404500446412800
score 15,812429

Similares en LA Referencia